Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Ampio Pharma Announces Pricing Of $15 Mln Stock Offering

RELATED NEWS
Trade AMPE now with 
7/12/2012 8:13 PM ET

Ampio Pharmaceuticals, Inc. (AMPE: Quote) said late Thursday that it has priced its underwritten public offering of 4,615,400 shares of its common stock, offered at a price to the public of $3.25 per share.

The gross proceeds to Ampio from the offering are expected to be $15.0 million, before deducting the underwriting discount and other estimated offering expenses payable by Ampio.

Ampio and certain of its shareholders have granted the underwriters a 45-day option to purchase at the public offering price up to an aggregate of 692,310 additional shares of common stock to cover overallotments, if any.

The offering is expected to close on or about July 18.

Click here to receive FREE breaking news email alerts for Ampio Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Confidence among Australian consumers declined sharply in May to its lowest level since August 2012, driven largely by negative responses to the Federal Budget, a survey by Westpac and Melbourne Institute showed Wednesday. The index of consumer sentiment fell 7 percent in May to 97.6 from 104.9 in April. This is the lowest reading since August 2012. Data-storage products maker NetApp Inc. said Tuesday after the markets closed that its fourth quarter profit fell 4% from last year, hurt mainly by higher operating expenses even as revenue grew slightly. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Analog Devices, Inc. said that its second quarter profit rose slightly from last year, helped mainly by lower income tax expenses even as revenue declined 2%. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations. However, the company forecast third quarter revenue and earnings below analysts' current consensus estimates.
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.